Press Release – C2 Pharma

C2 PHARMA Receives CEP approval for Oxybuprocaine Hydrochloride

Posted on 28. January 202528. January 2025 by admin_c2p

C2 PHARMA Receives CEP Approval For Tropicamide

Posted on 30. July 202430. July 2024 by admin_c2p

C2 PHARMA’s Upcoming Launch of Oxybuprocaine Hydrochloride

Posted on 6. March 20246. March 2024 by admin_c2p

C2 PHARMA Receives DMF Approval in China for Pilocarpine Nitrate

Posted on 21. November 202322. November 2023 by admin_c2p

C² PHARMA Expands API Portfolio with Global Regulatory Access Ahead of CPhI Barcelona

Posted on 17. October 202317. October 2023 by admin_c2p

EDQM Grants C2 PHARMA CEP Approval for Commercial Sale of Cyclopentolate Hydrochloride

Posted on 27. June 202327. June 2023 by admin_c2p

C2 PHARMA Receives Approval for Digoxin China DMF, Becoming China’s Only European Supplier of This API

Posted on 13. June 202327. June 2023 by admin_c2p

C² PHARMA Completes Multiple Local Regulatory Filings and Expands Portfolio

Posted on 9. November 202116. May 2023 by admin

C² PHARMA Completes Multiple Regulatory Filings, Expands Portfolio

Posted on 23. February 202116. May 2023 by admin

C² PHARMA Acquires Digoxin API Portfolio from Nobilus Ent

Posted on 20. March 201923. February 2021 by admin

Validation

Posted on 4. October 20183. October 2022 by admin

C2 PHARMA leads

Posted on 4. October 20183. October 2022 by admin

Acquisition

Posted on 22. June 20181. October 2018 by admin

Willkommen zur deutschen Version von WordPress. Dies ist der erste Beitrag. Du kannst ihn bearbeiten oder löschen. Und dann starte mit dem Schreiben!